Magnus Financial Group LLC raised its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 15.2% during the third quarter, HoldingsChannel.com reports. The fund owned 896 shares of the medical research company’s stock after acquiring an additional 118 shares during the quarter. Magnus Financial Group LLC’s holdings in Amgen were worth $289,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of AMGN. Fisher Asset Management LLC grew its stake in Amgen by 4.0% during the fourth quarter. Fisher Asset Management LLC now owns 78,753 shares of the medical research company’s stock worth $22,682,000 after buying an additional 3,049 shares during the last quarter. Nomura Holdings Inc. acquired a new position in shares of Amgen in the 4th quarter worth approximately $3,104,000. Massmutual Trust Co. FSB ADV grew its position in Amgen by 12.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 6,939 shares of the medical research company’s stock worth $1,973,000 after acquiring an additional 787 shares during the last quarter. Farmers Trust Co. increased its holdings in Amgen by 15.9% during the 1st quarter. Farmers Trust Co. now owns 2,295 shares of the medical research company’s stock valued at $653,000 after purchasing an additional 314 shares in the last quarter. Finally, Lynch & Associates IN raised its position in Amgen by 29.8% in the 1st quarter. Lynch & Associates IN now owns 4,594 shares of the medical research company’s stock valued at $1,306,000 after purchasing an additional 1,055 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Amgen Trading Up 0.1 %
Shares of NASDAQ AMGN opened at $325.09 on Wednesday. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. Amgen Inc. has a twelve month low of $249.70 and a twelve month high of $346.85. The company’s fifty day moving average is $325.97 and its 200-day moving average is $311.49. The stock has a market cap of $174.39 billion, a price-to-earnings ratio of 46.44, a P/E/G ratio of 2.86 and a beta of 0.61.
Amgen Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.77%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s payout ratio is currently 128.57%.
Analyst Ratings Changes
Several brokerages have recently commented on AMGN. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $305.00 target price (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Jefferies Financial Group restated a “buy” rating and issued a $380.00 price objective (up previously from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 target price on shares of Amgen in a research report on Thursday, September 26th. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Finally, TD Cowen upped their price objective on Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $326.95.
Check Out Our Latest Research Report on AMGN
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Recommended Stories
- Five stocks we like better than Amgen
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- What is Insider Trading? What You Can Learn from Insider Trading
- AMD Gains Momentum With AI: Can It Beat Expectations?
- About the Markup Calculator
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.